Apixaban Management for Ureteroscopy in an 82-Year-Old Female with Atrial Fibrillation
Apixaban does not need to be held before ureteroscopy and can be continued throughout the procedure. 1
Pre-Procedure Management
Continue apixaban without interruption. The ICUD/AUA guidelines explicitly state that "ureteroscopy can be performed with continuing oral AC/AP therapy" 1. This recommendation applies to all anticoagulants and antiplatelet agents, including direct oral anticoagulants like apixaban.
Rationale for Continuation
- Ureteroscopy is classified as a low bleeding risk procedure where the bleeding would be non-critical in location and easily controlled
- The thrombotic risk of stopping anticoagulation in an 82-year-old with atrial fibrillation (high CHA2DS2-VASc score due to age and sex alone) outweighs the minimal bleeding risk
- The guideline specifically addresses ureteroscopy as distinct from higher-risk urological procedures like percutaneous nephrolithotomy, which do require anticoagulation interruption 1
Post-Procedure Management
Resume or continue apixaban immediately after the procedure without any holding period. Since the medication doesn't need to be stopped pre-procedure, there is no post-procedure restart consideration.
Important Clinical Context
The 2022 CHEST guidelines 2 classify procedures by bleeding risk, and while ureteroscopy isn't explicitly listed, the ICUD/AUA guidelines take precedence here as they are procedure-specific and directly address ureteroscopy. The CHEST guidelines would classify most ureteroscopies as low-to-moderate bleeding risk, which would suggest only 1 day off apixaban if interruption were needed—but the urological guidelines supersede this with their specific recommendation for continuation.
Critical Caveats
If the urologist insists on holding apixaban (despite guideline recommendations), the approach would be:
- Pre-procedure: Hold for 24 hours before the procedure (1 day = approximately 2 half-lives for low-moderate bleeding risk) 2, 3
- Post-procedure: Resume 24 hours after the procedure once adequate hemostasis is established 3
- No bridging therapy is needed given apixaban's rapid onset/offset 2
However, this interruption strategy should be strongly discouraged as it contradicts specialty society guidelines and unnecessarily increases stroke risk in this high-risk patient (age 82 = automatic CHA2DS2-VASc ≥3).
Special Considerations for This Patient
At age 82, this patient may already be on the reduced dose of apixaban (2.5 mg twice daily) if she meets dose-reduction criteria (age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL) 3. The continuation recommendation applies regardless of dose.
The key message: Ureteroscopy is safe with ongoing anticoagulation, and stopping apixaban creates unnecessary stroke risk in this elderly patient with atrial fibrillation.